A patient in Southern California who underwent breast reconstruction surgery using an off-label Seri surgical scaffold is pushing for the state to prosecute the operating plastic surgeon, despite having received $1 million in a settlement, over claims that he altered her medical records, according to a Pasadena Star News report. The patient, Wendy Knecht, underwent […]
Sofregen Medical said today that it bought the Seri surgical scaffold from Allergan (NYSE:AGN) for an undisclosed amount. Polaris Partners and other investors provided financing for the acquisition, according to the Medford, Mass.-based company. Seri, which is approved by the FDA for use as soft tissue support in plastic and reconstructive surgical procedures, is the only approved […]
Sofregen Medical said yesterday that it landed a $6.2 million Series A round from Polaris Partners and other founding investors, bringing their total funding raised to more than $11 million. The Medford, Mass.-based company was founded in 2014 to advance silk-based medical technology developed at Tufts University and the University of Pittsburgh for soft tissue […]
The FDA warned Allergan last month about marketing the Seri surgical scaffold in the U.S. for breast surgery indications without marketing clearance or approval. An FDA review of Allergan’s Seri website reported the scaffold was being marketted for breast surgery applications, which the federal watchdog says “would constitute a major change or modification to its […]
Allergan Inc. (NYSE:AGN) acquired Serica Technologies Inc. for an undisclosed amount.
Medford, Mass.-based Serica, which is developing silk-based biomaterials for tissue repair, will become a wholly owned subsidiary of Irvine, Calif.-based Allergan, which makes products ranging from Botox to Lap-Band gastric banding systems.
Thirteen years ago Greg Altman, president and CEO of Serica Technologies Inc., blew out his knee playing football. After reconstructive surgery on his ruptured anterior cruciate ligament, the former All-American at Tufts University found the rehabilitation process so challenging that he set out to develop an alternative.
The U.S. Food and Drug Administration hopped onto Serica Technologies Inc.’s SeriScaffold product, granting the silk-based surgical mesh clearance to hit the market.
The Medford-based growth-stage device maker’s flagship product is designed to repair and remodel damaged connective tissue, avoiding the erosion and scar formation that can result from surgery.